CSL Behring Expands Operations to Russia

CSL Behring is opening operations in Russia in order to provide more patients with greater access to treatment. This is particularly significant in Russia where the healthcare system has some unmet needs for state-of-the-art biotherapies and blood plasma products.

CSL Behring CEO and Managing Director Paul Perreault, said the new office enables CSL Behring to partner more closely with the Russian Federation, healthcare providers, patient groups and the scientific community. He noted CSL Behring will be closer to patients, listen to them more carefully, and better understand their medical needs. The company currently has seven products registered in Russia.

“It is this process of listening and engaging that enhances our ability to deliver new and innovative medicines that make such a huge difference in people’s lives,” Perreault said. He added that it will now be easier to launch products in Russia and offer new therapy options to doctors and their patients.

In addition, CSL Behring is investigating opportunities to contribute to the development of the Russian pharmaceutical industry, and identify the best ways to partner with the Russian government. As an example, because the amount of human plasma that is currently collected in Russia is insufficient to meet the growing demand for protein-based medicines, Perreault said it may be possible to transfer CSL Behring’s plasma collection technology to Russia, and initiate toll manufacturing in that country.

(Source: CSL Behring)

 

2015-12-10T20:35:29+00:00